This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.
1. Merli G, Vanscoy G, et al. Applying scientific criteria to therapeutic interchange: A balanced analysis of low molecular weight heparins. J Thromb Thrombolysis2001;11(3):247-247.
2.
2. American Society of Hospital Pharmacists. ASHP statement on the formulary system. Am J Hosp Pharmacol1988;43;2839-2839.
3.
3. McCart GM, Kayser S.Therapeutic equivalency of low molecular weight heparins. Ann Pharmacother2002;36:1042-1042.
4.
4. Prandoni P.Low molecular weight heparins: Are they interchangeable? Yes. J Thromb Hemost2003;1:10-10.
5.
5. Nenci G.Low molecular weight heparins: Are they interchangeable? No. J Thromb Hemostas2003;1:12-12.
6.
6. Bick RL, Fareed J.Low molecular weight heparin: Differences and similarities in approved preparations in the United States. Clin Appl Throm Hemost1999;5(Suppl 1):S63-S63.
7.
7. Fareed J, Hoppensteadt D, Jeske W, Clarizio R, Walenga JM.Low molecular weight heparins. Are they different?Can J Cardiol1998;14(Suppl E):28E-28E.
8.
8. Fareed J, Haas S, Sasahara A. Past, present and future considerations on low molecular weight heparins differentiation: An epilogue. Semin Thromb Hemost1999;25(Suppl 3):145-145.
9.
9. Nightingale SL.From the Food and Drug Administration. JAMA1993;270(14):1672-1672.
10.
10. Hirsch J, Warkentin TE, et al. Heparin and low molecular weight heparin: Mechanisms of action, pharamcokinetics, dosing considerations, monitoring, efficacy, and safety. Chest1998;114(Suppl 5):489S-489S.
11.
11. Ryan TJ, Antman EM, et al. 1999 update ACC/AHA guidelines for the management of patients with acute myocardial infarction. JAm Coll Cardiol1999;34(3):890-890.
12.
12. Fareed J, Fu K, et al. Pharmacokinetics of low molecular weight heparins in animal models. Semin Thromb Hemost1999;25(Suppl 3):51-51.
13.
13. Kaiser B, Kirchmaier CM, et al. Preclinical biochemistry and pharmacology of low molecular weight hepains in vivo. Semin Thromb Hemost1999;25(Suppl 3):35-35.
14.
14. Cohen M, Demers C, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q wave coronary events study group (ESSENCE). N Engl J Med1997;337(7):447-447.
15.
15. Klein W, Buchwald A, et al. Fragmin in unstable angina pectoris or in non-Q wave acute myocardial infarction. Fragmin in unstable coronary artery disease (FRIC). Am J Cardiol1997;80(5A):30E-30E.
16.
16. FRISC study group. Low molecular weight heparin during instability in coronary artery disease. Fragmin during instability in coronary artery disease (FRISC). Lancet1998;347(9001):561-561.
17.
17. Mousa S, Fareed J. Overview: From heparin to low molecular weight heparins: Beyond anticoagulation. Curr Opin Invest Drug2001;2(8):1077-1077.
18.
18. Hirsch J, Fuster V, et al. American Heart Association/ American College of Cardiology foundation guide to warfarin therapy. Circulation2003;107:1692-1692.
